KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Recursion Pharmaceuticals (RXRX) Net Income towards Common Stockholders (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Net Income towards Common Stockholders for 6 consecutive years, with -$108.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Net Income towards Common Stockholders rose 39.56% year-over-year to -$108.1 million, compared with a TTM value of -$644.8 million through Dec 2025, down 39.06%, and an annual FY2025 reading of -$644.8 million, down 39.06% over the prior year.
  • Net Income towards Common Stockholders was -$108.1 million for Q4 2025 at Recursion Pharmaceuticals, up from -$162.3 million in the prior quarter.
  • Across five years, Net Income towards Common Stockholders topped out at -$30.5 million in Q1 2021 and bottomed at -$202.5 million in Q1 2025.
  • Average Net Income towards Common Stockholders over 5 years is -$93.2 million, with a median of -$84.0 million recorded in 2023.
  • The sharpest move saw Net Income towards Common Stockholders tumbled 153.94% in 2021, then soared 39.56% in 2025.
  • Year by year, Net Income towards Common Stockholders stood at -$65.0 million in 2021, then increased by 6.12% to -$61.0 million in 2022, then tumbled by 52.5% to -$93.0 million in 2023, then tumbled by 92.38% to -$178.9 million in 2024, then soared by 39.56% to -$108.1 million in 2025.
  • Business Quant data shows Net Income towards Common Stockholders for RXRX at -$108.1 million in Q4 2025, -$162.3 million in Q3 2025, and -$171.9 million in Q2 2025.